Insights

Blog: Life Sciences – Counsel Pulse

Thought Leadership

Psychedelic Drug Development Takes Center Stage – Do You Have What it Takes to Bring a Psychedelic Drug to Market?

See all blog: life sciences – counsel pulse

FDA Leadership Provides Revised Priorities at Reagan-Udall Foundation Annual Board of Directors Meeting

FDA Commissioner – Year in Review … What’s Next?

DEA Taking Steps to Issue Temporary Scheduling Order for Kratom-Based Products Including High Levels of 7-OH and 7-OH-Related Synthetic Components

FDA’s First New Sunscreen Active Ingredient in Decades: Regulatory Exclusivity and Commercial Implications

Operation TrialBlazer Launches to Restore U.S. Leadership to Clinical Trials

FDA Reports Meeting Year One Goals for Reducing Animal Drug Testing

See all blog: life sciences – counsel pulse

Media Contact

Taylor Hayslett

thayslett@spencerfane.com | 816.292.8859

thayslett@spencerfane.com

816-292-8859